Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04154943
Title Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Regeneron Pharmaceuticals
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | DEU | AUS

Facility Status City State Zip Country Details
Regeneron Study Site Palo Alto California 94304 United States Details
Regeneron Study Site Washington District of Columbia 20037 United States Details
Regeneron Study Site Miami Florida 33176 United States Details
Regeneron Study Site Tampa Florida 33612 United States Details
Regeneron Study Site Baltimore Maryland 21231 United States Details
Regeneron Study Site Boston Massachusetts 02114 United States Details
Regeneron Study Site Boston Massachusetts 02215 United States Details
Regeneron Study Site Ann Arbor Michigan 48109 United States Details
Regeneron Study Site Omaha Nebraska 68114 United States Details
Regeneron Study Site New York New York 10065 United States Details
Regeneron Study Site Charlotte North Carolina 28204 United States Details
Regeneron Study Site Durham North Carolina 27710 United States Details
Regeneron Study Site Cleveland Ohio 44195 United States Details
Regeneron Study Site Dallas Texas 75390 United States Details
Regeneron Study Site Houston Texas 77030 United States Details
Regeneron Study Site St Leonards New South Wales 2065 Australia Details
Regeneron Study Site Herston Queensland 4029 Australia Details
Regeneron Study Site Melbourne Victoria 3000 Australia Details
Regeneron Study Site Dresden 01307 Germany Details
Regeneron Study Site Essen 45147 Germany Details
Regeneron Study Site Kiel 24105 Germany Details
Regeneron Study Site Tübingen 72076 Germany Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field